Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2013 1
2014 3
2015 1
2016 1
2017 3
2018 2
2019 2
2020 3
2021 1
2022 2
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Correction to: Psychiatric Disorders in Adolescent and Young Adult-Onset Cancer Survivors: A Systematic Review and Meta-Analysis by De R, Zabih V, Kurdyak P, Sutradhar R, Nathan PC, McBride ML, and Gupta S. J Adolesc Young Adult Oncol. 2020;9(1):12-22. DOI: 10.1089/jayao.2019.0097.
[No authors listed] [No authors listed] J Adolesc Young Adult Oncol. 2020 Jun;9(3):455-456. doi: 10.1089/jayao.2019.0097.correx. Epub 2020 May 5. J Adolesc Young Adult Oncol. 2020. PMID: 32379518 Free PMC article. No abstract available.
Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
Hahn E, Rodin D, Sutradhar R, Nofech-Mozes S, Trebinjac S, Paszat LF, Rakovitch E. Hahn E, et al. Curr Oncol. 2023 Jun 13;30(6):5795-5806. doi: 10.3390/curroncol30060433. Curr Oncol. 2023. PMID: 37366916 Free PMC article. Review.
Novel EGFR-MAPK kinase and ABC transporter inhibitors for HepG2 resistant to Erlotinib.
Ostlund T, SutraDhar K, Elgazwi SM, Mahnashi M, Kyeremateng J, Iram S, Halaweish F. Ostlund T, et al. Drug Dev Res. 2023 Apr;84(2):200-210. doi: 10.1002/ddr.22023. Epub 2022 Dec 9. Drug Dev Res. 2023. PMID: 36484285
Lead compounds MMA132 and MMA102 showed 13 and 20 M IC(50) values, respectively against HepG2-R resistant to Erlotinib. These compounds showed cell cycle arrest of the G2 phase up to 54%, and inhibited cell migration of HepG2-R cells up to 48 h. ...Western blot anal …
Lead compounds MMA132 and MMA102 showed 13 and 20 M IC(50) values, respectively against HepG2-R resistant to Erlotinib. These compoun …
30 results